JPH0899858A - Skin external agent - Google Patents

Skin external agent

Info

Publication number
JPH0899858A
JPH0899858A JP6261943A JP26194394A JPH0899858A JP H0899858 A JPH0899858 A JP H0899858A JP 6261943 A JP6261943 A JP 6261943A JP 26194394 A JP26194394 A JP 26194394A JP H0899858 A JPH0899858 A JP H0899858A
Authority
JP
Japan
Prior art keywords
rutin
extract
water
skin
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6261943A
Other languages
Japanese (ja)
Inventor
Ichiro Sasaki
一郎 佐々木
Akiyoshi Takayama
明美 高山
Shinji Kobayashi
伸次 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kose Corp
Original Assignee
Kose Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kose Corp filed Critical Kose Corp
Priority to JP6261943A priority Critical patent/JPH0899858A/en
Publication of JPH0899858A publication Critical patent/JPH0899858A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE: To obtain skin external agent containing a water-soluble rutin and an anti-inflammatory agent as active components, having high stability and excellent anti-inflammatory and beautifying effect, and accordingly capable of exhibiting strong suppressing effect against the inflammation of skin by sunburn and the pigmentation after sunburn. CONSTITUTION: This external agent contains a water-soluble rutin [preferably, α-glycosylrutin of the formula (R is glucose, mannose, etc.); the content of rutin is 10-85wt.%] and an anti-inflammatory agent (preferably, glycyrrhizinic acid, glycyrrhetinic acid, an extract of chamomile, etc.) as active components. The content of the water-soluble rutin is preferably 0.00001-5wt.% in terms of rutin. That of the anti-inflammatory agent is preferably 0.01-3wt.%. Further, α- glycosylrutin of the formula is obtained e.g. by mixing rutin with starchiness such as dextrin followed by an enzymatic reaction.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、皮膚外用剤に関し、さ
らに詳しくは、優れた皮膚炎症防止効果、美白効果を有
する化粧品、医薬品等の皮膚外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin external preparation, and more particularly to a skin external preparation such as cosmetics and pharmaceuticals having excellent skin inflammation-preventing and whitening effects.

【0002】[0002]

【従来の技術】従来、日焼けによる皮膚の炎症を抑える
ために、カラミン等の抗炎症効果を有する薬剤が、ま
た、日焼け後の色素沈着を抑えるためには、アスコルビ
ン酸、グルタチオン等の美白効果を有する薬剤がそれぞ
れ皮膚外用剤の成分として用いられていたが、これらの
薬効成分を配合した皮膚外用剤は、抗炎症効果や美白効
果が弱く、十分な日焼け防止効果があるとはいい難かっ
た。
2. Description of the Related Art Conventionally, agents having an anti-inflammatory effect such as calamine have been used to suppress skin inflammation due to sunburn, and whitening effects such as ascorbic acid and glutathione have been used to suppress pigmentation after sunburn. Each of the drugs has been used as a component of the external preparation for skin, but the external preparation for skin containing these medicinal components has a weak anti-inflammatory effect and a whitening effect, and it is hard to say that it has a sufficient sunburn preventing effect.

【0003】一方、ルチンは、ソバの全草のほか、ジャ
ガイモ、アスパラガス、アンズ、サクランボ、トマト、
イチジク、柑橘類、アズキなどの野菜や果物、又ハチミ
ツ、緑茶などにも広く含まれる化合物であり、酸化防
止、紫外線吸収、血管補強等の種々の作用が知られてい
るが、水にはほとんど溶けないことから、あまり利用さ
れないものであった。
On the other hand, rutin is not only whole buckwheat but also potatoes, asparagus, apricots, cherries, tomatoes,
It is a compound widely contained in vegetables and fruits such as figs, citrus fruits and adzuki beans, as well as honey and green tea, and is known to have various actions such as antioxidant, UV absorption, and blood vessel reinforcement, but it is almost soluble in water. Since it was not there, it was not used very often.

【0004】そこで、ルチンの水溶性を高め、これを化
粧料に配合利用することも試みられてきた(特開平3−
27293号、同3−58790号、同3−11529
2号、同3−275607号、同3−275608号
等)。
Therefore, it has been attempted to enhance the water solubility of rutin and use it in a cosmetic composition (Japanese Patent Laid-Open No. 3-30083).
No. 27293, No. 3-58790, No. 3-11529.
No. 2, No. 3-275607, No. 3-275608, etc.).

【0005】[0005]

【発明が解決しようとする課題】しかしながら、水溶性
ルチン単独ではその効果を十分に発揮させることは難し
く、また目的達成の為には多量に配合する必要があり、
水溶性ルチンによる着色が外観上問題になることもあっ
た。
However, it is difficult to sufficiently exert the effect of water-soluble rutin alone, and it is necessary to add a large amount of water-soluble rutin in order to achieve the object.
Coloring with water-soluble rutin sometimes caused a problem in appearance.

【0006】[0006]

【課題を解決するための手段】そこで、本発明者等は、
水溶性ルチンの有する効果を十分に利用した皮膚外用剤
を得べく、鋭意研究を行なった結果、水溶性ルチンと皮
膚外用剤に応用される抗炎症剤とを組み合わせることに
より、前記問題点を解決し、日焼けによる皮膚の炎症
と、日焼け後の色素沈着を抑える効果を相乗的に有する
皮膚外用剤が得られることを見出し、本発明を完成し
た。
Therefore, the present inventors have
As a result of intensive research to obtain a skin external preparation that fully utilizes the effects of water-soluble rutin, by combining water-soluble rutin and an anti-inflammatory agent applied to the skin external preparation, the above problems are solved. However, they have found that an external preparation for skin having a synergistic effect of suppressing skin inflammation due to sunburn and pigmentation after sunburn can be obtained, and completed the present invention.

【0007】すなわち本発明は、水溶性ルチンと抗炎症
剤とを有効成分として含有することを特徴とする皮膚外
用剤を提供するものである。
[0007] That is, the present invention provides a skin external preparation characterized by containing water-soluble rutin and an anti-inflammatory agent as active ingredients.

【0008】本発明の必須成分である水溶性ルチンは、
上記の如くルチンの水溶性を高めたものであれば良く、
特に限定するものではないが、例えば、ルチンにデキス
トリン等の澱粉質を混合し、酵素反応によりルチンにグ
ルコース、マルトース、マルトトリオース、マルトテト
ラオース等の転移した一般式化1で示されるα−グリコ
シルルチンが好適に用いられる。これらは1種又は2種
以上組み合わせて用いても良く、ルチン含量が10〜8
5重量%のものが好ましい。
The water-soluble rutin which is an essential component of the present invention is
As long as the water solubility of rutin is increased as described above,
Although not particularly limited, for example, by mixing a starch substance such as dextrin with rutin and transferring glucose, maltose, maltotriose, maltotetraose or the like to rutin by an enzymatic reaction, α-represented by the general formula 1 Glycosyl rutin is preferably used. These may be used alone or in combination of two or more, and have a rutin content of 10 to 8
It is preferably 5% by weight.

【0009】[0009]

【化1】 [Chemical 1]

【0010】本発明の皮膚外用剤における水溶性ルチン
の含有量は、ルチン換算で、好ましくは0.00001
〜5重量%(以下単に「%」で示す)(未反応デキスト
リンを含む粉末として好ましくは0.0001〜10
%、より好ましくは0.01〜5%)である。
The content of water-soluble rutin in the external preparation for skin of the present invention is preferably 0.00001 in terms of rutin.
˜5% by weight (hereinafter referred to simply as “%”) (preferably 0.0001 to 10 as powder containing unreacted dextrin)
%, More preferably 0.01 to 5%).

【0011】有効成分である水溶性ルチンの含有量が
0.00001%より少ないと十分な効果は得られない
ことがあり、また、5%を超えて配合してもそれ以上の
効果の増大は見られない。
If the content of the water-soluble rutin as an active ingredient is less than 0.00001%, a sufficient effect may not be obtained, and if the content exceeds 5%, the effect is further increased. can not see.

【0012】一方、本発明の他の必須成分である抗炎症
剤としては、グリチルリチン酸、グリチルレチン酸、メ
フェナム酸、フェニルブタゾン、インドメタシン、イブ
プロフェン、ケトプロフェン、アラントイン、グアイア
ズレン及びそれらの誘導体並びにそれらの塩、ε−アミ
ノカプロン酸、酸化亜鉛、ジクロフェナクナトリウム、
カンゾウ抽出物、アロエ抽出物、シコン抽出物、サルビ
ア抽出物、アルニカ抽出物、カミツレ抽出物、シラカバ
抽出物、オトギリソウ抽出物、ユーカリ抽出物、ムクロ
ジ抽出物等が挙げられる。
On the other hand, the anti-inflammatory agent which is another essential component of the present invention includes glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, allantoin, guaiazulene and their derivatives and salts thereof. , Ε-aminocaproic acid, zinc oxide, diclofenac sodium,
Examples include licorice extract, aloe extract, shikon extract, salvia extract, arnica extract, chamomile extract, birch extract, hypericum extract, eucalyptus extract, mukurodi extract and the like.

【0013】これらの抗炎症剤のうち、特に好ましいも
のとしては、グリチルリチン酸、グリチルレチン酸、グ
アイアズレン及びそれらの誘導体並びにそれらの塩、ε
−アミノカプロン酸、カンゾウ抽出物、アロエ抽出物、
シコン抽出物、カミツレ抽出物が挙げられる。
Of these anti-inflammatory agents, glycyrrhizic acid, glycyrrhetinic acid, guaiazulene and their derivatives and salts thereof, and ε are particularly preferable.
-Aminocaproic acid, licorice extract, aloe extract,
Examples include shikon extract and chamomile extract.

【0014】これらの抗炎症剤の本発明皮膚外用剤中の
含有量は、一般には0.0001〜5%、好ましくは
0.01〜3%である。これらの抗炎症剤は1種又は2
種以上を組み合わせて用いることができる。
The content of these anti-inflammatory agents in the external preparation for skin of the present invention is generally 0.0001 to 5%, preferably 0.01 to 3%. One or two of these anti-inflammatory agents
A combination of two or more species can be used.

【0015】本発明の皮膚外用剤は、常法に従い、必須
成分である水溶性ルチン及び抗炎症剤とを通常の皮膚外
用剤として知られる種々の形態の基剤に配合して調製す
ることができる。
The skin external preparation of the present invention can be prepared by blending the essential components, water-soluble rutin and an anti-inflammatory agent, in various forms of bases known as ordinary skin external preparations, according to a conventional method. it can.

【0016】皮膚外用剤の形態の例としては、特に限定
されず、例えば、乳液、クリーム、化粧水、パック、フ
ァンデーション、毛髪化粧料、洗浄料等の化粧品の他、
分散液、軟膏剤、クリーム剤、外用液剤等の医薬品、医
薬部外品などとすることができる。
The form of the external preparation for skin is not particularly limited, and examples thereof include cosmetics such as milky lotion, cream, lotion, pack, foundation, hair cosmetic, and cleaning agent.
It may be a dispersion, an ointment, a cream, a drug such as a liquid for external use, a quasi drug, or the like.

【0017】外用剤の基剤としては、これら外用剤の形
態に応じた基剤、例えば、通常の皮膚外用剤に用いられ
る水性成分、粉体、界面活性剤、油剤、保湿剤、低級ア
ルコールや多価アルコール等のアルコール類、pH調整
剤、防腐剤、色素、酸化防止剤、増粘剤、香料、美容成
分等を必要に応じて配合することができる。
The base for external preparations is a base suitable for the form of these external preparations, for example, aqueous components, powders, surfactants, oils, humectants, lower alcohols and the like used in ordinary skin external preparations. If necessary, alcohols such as polyhydric alcohols, pH adjusters, preservatives, pigments, antioxidants, thickeners, fragrances, beauty ingredients and the like can be added.

【0017】[0017]

【実施例】次に、試験例及び実施例を挙げ本発明を更に
詳しく説明するが、本発明はこれらになんら制約される
ものではない。
EXAMPLES Next, the present invention will be described in more detail with reference to test examples and examples, but the present invention is not limited thereto.

【0019】試験例1 抗炎症効果及び美白効果:表1に示した薬剤及びエタノ
ール15% (v/v)を含み、残部が精製水からなる化粧水
を調製し、有色モルモット背部に塗布して日焼けによる
炎症及び色素沈着に対する効果を調べた。その結果を表
2に示す。
Test Example 1 Anti-inflammatory effect and whitening effect: A lotion containing the agents shown in Table 1 and ethanol 15% (v / v) and the remainder being purified water was prepared and applied to the back of a colored guinea pig. The effects on sunburn-induced inflammation and pigmentation were investigated. The results are shown in Table 2.

【0020】(試験方法)有色モルモット(各群10
匹)の背部を剃毛し、麻酔下紫外線を照射した。紫外線
照射は、東芝株式会社製FL20S・BLBランプとF
L20S・E30ランプを3本ずつ同時に照射し、紫外
線量は4.8×106 erg/cm2 とした。紫外線照
射の24時間前と照射直後及び照射12時間後、24時
間後にモルモット背部の4ヵ所に試料を0.2mlずつ
よく擦り込んだ。なお、紫外線照射前に塗布部位を温水
でよく洗浄した。照射24時間後に炎症の程度を、そし
て7日後に色素沈着の程度を観察した。
(Test method) Colored guinea pigs (10 for each group)
The back of each animal was shaved and irradiated with ultraviolet rays under anesthesia. UV irradiation is performed with Toshiba Corporation FL20S / BLB lamp and F
Three L20S / E30 lamps were simultaneously irradiated, and the amount of ultraviolet rays was 4.8 × 10 6 erg / cm 2. 0.2 ml of the sample was rubbed well into each of four places on the back of the guinea pig 24 hours before, immediately after the irradiation, and 12 hours after the irradiation, and 24 hours after the irradiation. The application site was thoroughly washed with warm water before irradiation with ultraviolet rays. The degree of inflammation was observed 24 hours after irradiation and the degree of pigmentation after 7 days.

【0021】[0021]

【表1】 [Table 1]

【0022】(評価基準) 炎症についての評価基準(抗炎症効果) 0:炎症が全く認められない 1:ごくわずか炎症が認められる 2:炎症は認められるが、非照射部位との境界は不明瞭 3:炎症が認められ、非照射部位との境界は鮮明(Evaluation criteria) Evaluation criteria for inflammation (anti-inflammatory effect) 0: No inflammation is observed 1: Very slight inflammation is observed 2: Inflammation is observed, but the boundary with the non-irradiated site is unclear 3: Inflammation was observed, and the boundary with the non-irradiated area was clear

【0023】色素沈着についての評価基準(美白効果) 0:色素沈着が全く認められない 1:ごくわずか色素沈着が認められる 2:色素沈着は認められるが、非照射部位との境界は不
明瞭 3:色素沈着は認められ、非照射部位との境界は鮮明
Evaluation criteria for pigmentation (whitening effect) 0: No pigmentation is observed at all 1: Very slight pigmentation is observed 2: Pigmentation is observed, but the boundary with the non-irradiated site is unclear 3 : Pigmentation is observed, and the boundary with the non-irradiated area is clear

【0024】上記評価基準に従い、それぞれの評点が1
点以下であるモルモットが10匹中何匹いたかを数え、
以下の判定基準に従って判定した。
According to the above evaluation criteria, each score is 1
Count how many out of 10 guinea pigs are below the score,
It judged according to the following judgment criteria.

【0025】(判定基準) 10匹中、評点1点以下のモルモット数が 8匹以上 : 著 効 6匹以上 : 有 効 4匹以上 : やや有効 3匹以下 : 無 効(Judgment Criteria) Among 10 animals, the number of guinea pigs with a rating of 1 point or less is 8 or more: Remarkable effect 6 or more: Effective 4 or more: Slightly effective 3 or less: Ineffective

【0026】[0026]

【表2】 [Table 2]

【0027】表2の結果より、水溶性ルチンとグリチル
リチン酸ジカリウム、グアイアズレン又はシコン抽出物
を配合した本発明の化粧水は、これらを単独で含む化粧
水に比べて抗炎症効果及び美白効果が優れていることが
明らかである。
From the results shown in Table 2, the lotion of the present invention containing water-soluble rutin and dipotassium glycyrrhizinate, guaiazulene or shikon extract is superior in anti-inflammatory effect and whitening effect to the lotion containing them alone. It is clear that

【0028】実施例1 クリーム:次に示す処方及び下記製法でクリームを調製
した。本発明のクリームは優れた皮膚炎症防止効果、美
白効果を有するものであった。 <処方> (配合量)% (1)ポリオキシエチレンモノステアレート(40E.O.) 2.0 (2)グリセリルモノステアレート(自己乳化型) 5.0 (3)ステアリン酸 5.0 (4)ベヘニルアルコール 0.5 (5)スクワラン 15.0 (6)イソオクタン酸セチル 5.0 (7)ブチルパラベン 0.1 (8)メチルパラベン 0.1 (9)1,3−ブチレングリコール 5.0 (10)グリチルリチン酸ジカリウム(注1) 0.2 (11)水溶性ルチン(注2) 0.5 (12)精製水 残量 (13)香料 0.1 (注1)丸善製薬社製 (注2)ルチンにグルコース一残基を転移して得られた、ルチン含量として8 0%のもの
Example 1 Cream: A cream was prepared by the following formulation and the following production method. The cream of the present invention had an excellent skin inflammation preventing effect and whitening effect. <Prescription> (Amount of compounding)% (1) Polyoxyethylene monostearate (40E.O.) 2.0 (2) Glyceryl monostearate (self-emulsifying type) 5.0 (3) Stearic acid 5.0 ( 4) Behenyl alcohol 0.5 (5) Squalane 15.0 (6) Cetyl isooctanoate 5.0 (7) Butylparaben 0.1 (8) Methylparaben 0.1 (9) 1,3-Butylene glycol 5.0 ( 10) Dipotassium glycyrrhizinate (Note 1) 0.2 (11) Water-soluble rutin (Note 2) 0.5 (12) Purified water balance (13) Perfume 0.1 (Note 1) Maruzen Pharmaceutical Co., Ltd. (Note 2) ) A rutin content of 80% obtained by transferring one glucose residue to rutin

【0029】<製法> A.成分(1)〜(7)を70℃にて加熱溶解する。 B.成分(8)〜(12)を70℃にて加熱溶解する。 C.AをBに加え、乳化する。 D.Cに成分(13)を加え、冷却してクリームを得
る。
<Production Method> A. Components (1) to (7) are heated and dissolved at 70 ° C. B. Components (8) to (12) are heated and dissolved at 70 ° C. C. Add A to B and emulsify. D. Ingredient (13) is added to C and cooled to obtain a cream.

【0030】実施例2 乳液:次に示す処方及び下記製法で乳液を調製した。本
発明の乳液は優れた皮膚炎症防止効果、美白効果を有す
るものであった。 <処方> (配合量)% (1)ポリオキシエチレンソルビタン 1.0 モノステアレート(10E.O.) (2)ポリオキシエチレンソルビット 0.5 テトラオレエート(60E.O.) (3)グリセリルモノステアレート 1.0 (4)ステアリン酸 0.5 (5)ベヘニルアルコール 0.5 (6)精製アボガド油 4.0 (7)トリ2−エチルヘキサン酸グリセリル 4.0 (8)ブチルパラベン 0.1 (9)水溶性ルチン(注) 0.5 (10)グアイアズレン 0.2 (11)メチルパラベン 0.1 (12)カルボキシビニルポリマー 0.07 (13)1,3−ブチレングリコール 5.0 (14)精製水 残量 (15)水酸化ナトリウム 0.025 (16)精製水 7.5 (17)香料 0.1 (注)ルチンにグルコース一残基を転移して得られた、ルチン含量として60 %のもの
Example 2 Emulsion: An emulsion was prepared by the following formulation and the following production method. The emulsion of the present invention has an excellent effect of preventing skin inflammation and a whitening effect. <Prescription> (Blended amount)% (1) Polyoxyethylene sorbitan 1.0 monostearate (10 EO) (2) Polyoxyethylene sorbit 0.5 tetraoleate (60 EO) (3) Glyceryl Monostearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Refined avocado oil 4.0 (7) Glyceryl tri-2-ethylhexanoate 4.0 (8) Butylparaben 0. 1 (9) Water-soluble rutin (Note) 0.5 (10) Guiaazulene 0.2 (11) Methylparaben 0.1 (12) Carboxyvinyl polymer 0.07 (13) 1,3-Butylene glycol 5.0 (14) ) Purified water Remainder (15) Sodium hydroxide 0.025 (16) Purified water 7.5 (17) Perfume 0.1 (Note) Rutin has one glucose residue Obtained in metastasis, of 60% by rutin content

【0031】<製法> A.成分(1)〜(10)を70℃にて加熱溶解する。 B.成分(11)〜(14)を70℃にて加熱溶解す
る。 C.AをBに加え、乳化する。 D.Cに(15)〜(17)を加え、冷却してクリーム
を得る。
<Manufacturing Method> A. Components (1) to (10) are heated and dissolved at 70 ° C. B. Components (11) to (14) are heated and dissolved at 70 ° C. C. Add A to B and emulsify. D. (15) to (17) are added to C and cooled to obtain a cream.

【0032】実施例3 化粧水:次に示す処方及び下記製法で乳液を調製した。
本発明の乳液は優れた皮膚炎症防止効果、美白効果を有
するものであった。 <処方> (配合量)% (1)ポリオキシエチレン硬化ヒマシ油(60E.O.) 1.0 (2)香料 適量 (3)エタノール 10.0 (4)メチルパラベン 0.1 (5)ε−アミノカプロン酸 0.3 (6)クエン酸 0.1 (7)クエン酸ナトリウム 0.3 (8)1,3−ブチレングリコール 5.0 (9)水溶性ルチン(注) 0.01 (10)精製水 残量 (注)ルチンにグルコース一残基を転移して得られた、ルチン含量として80 %のもの
Example 3 Lotion: An emulsion was prepared by the following formulation and the following production method.
The emulsion of the present invention has an excellent effect of preventing skin inflammation and a whitening effect. <Prescription> (Blended amount)% (1) Polyoxyethylene hydrogenated castor oil (60 EO) 1.0 (2) Perfume proper amount (3) Ethanol 10.0 (4) Methylparaben 0.1 (5) ε- Aminocaproic acid 0.3 (6) Citric acid 0.1 (7) Sodium citrate 0.3 (8) 1,3-Butylene glycol 5.0 (9) Water-soluble rutin (Note) 0.01 (10) Purification Remaining water content (Note) 80% rutin content obtained by transferring one glucose residue to rutin

【0033】<製法> A.成分(1)〜(5)を70℃にて加熱溶解する。 B.成分(6)〜(10)を70℃にて加熱溶解する。 C.BをAに加え、攪拌して化粧水を得る。<Production Method> A. Components (1) to (5) are heated and dissolved at 70 ° C. B. Components (6) to (10) are heated and dissolved at 70 ° C. C. Add B to A and stir to obtain lotion.

【0034】実施例4 クリーム:以下に示す処方及び下記製法でクリームを調
製した。本発明のクリームは優れた皮膚炎症防止効果、
美白効果を有するものであった。 <処方> (配合量)% (1)ミツロウ 6.0 (2)セタノール 5.0 (3)還元ラノリン 5.0 (4)スクワラン 30.0 (5)グリセリンモノステアレート 4.0 (6)親油型モノステアリン酸グリセリン 2.0 (7)ポリオキシエチレンソルビタンモノ 2.0 ラウリン酸エステル(20E.O.) (8)水溶性ルチン(注1) 0.1 (9)抗炎症剤(注2) (10)防腐剤 0.2 (11)香料 0.1 (12)精製水 残量 (注1)ルチンにグルコース一残基を転移して得られた、ルチン含量として8 0%のもの (注2)配合抗炎症剤及びその配合量は表3に示す。
Example 4 Cream: A cream was prepared according to the following formulation and the following production method. The cream of the present invention has an excellent effect of preventing skin inflammation,
It had a whitening effect. <Prescription> (Blended amount)% (1) Beeswax 6.0 (2) Cetanol 5.0 (3) Reduced lanolin 5.0 (4) Squalane 30.0 (5) Glycerin monostearate 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene sorbitan mono 2.0 lauric acid ester (20 EO) (8) Water-soluble rutin (Note 1) 0.1 (9) Anti-inflammatory agent ( Note 2) (10) Preservative 0.2 (11) Perfume 0.1 (12) Purified water Remaining amount (Note 1) Obtained by transferring one glucose residue to rutin, which has a rutin content of 80%. (Note 2) Table 3 shows the compounded anti-inflammatory agents and their compounding amounts.

【0035】[0035]

【表3】 [Table 3]

【0036】<製法> A.成分(1)〜(7)、(10)及び(11)を混合
し、加熱して70℃に保つ。 B.成分(8)〜(9)及び(12)を混合し、加熱し
て70℃に保つ。 C.AにBを加えて混合し、30℃まで冷却してクリー
ムを得た。
<Production Method> A. Ingredients (1)-(7), (10) and (11) are mixed, heated and kept at 70 ° C. B. Ingredients (8)-(9) and (12) are mixed and heated to maintain 70 ° C. C. B was added to A and mixed, and cooled to 30 ° C. to obtain a cream.

【0037】[0037]

【発明の効果】本発明の皮膚外用剤は、安定で且つ優れ
た抗炎症作用及び美白作用を有するため、日焼けによる
皮膚の炎症や日焼け後の色素沈着に高い抑制効果を発揮
し、美容や医療において極めて有用なものである。 以 上
EFFECTS OF THE INVENTION Since the external preparation for skin of the present invention has stable and excellent anti-inflammatory action and whitening action, it exerts a high inhibitory effect on skin inflammation due to sunburn and pigmentation after sunburn, and is effective for beauty and medical treatment. It is extremely useful in. that's all

フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 7/00 K W X 7/42 31/70 ADA 35/78 C 8217−4C V 8217−4C J 8217−4C Q 8217−4C T 8217−4C E 8217−4C Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location A61K 7/00 K W X 7/42 31/70 ADA 35/78 C 8217-4C V 8217-4C J 8217- 4C Q 8217-4C T 8217-4C E 8217-4C

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 水溶性ルチンと抗炎症剤とを有効成分と
して含有することを特徴とする皮膚外用剤。
1. A skin external preparation containing water-soluble rutin and an anti-inflammatory agent as active ingredients.
【請求項2】 水溶性ルチンが、α−グリコシルルチン
である請求項1記載の皮膚外用剤。
2. The external preparation for skin according to claim 1, wherein the water-soluble rutin is α-glycosyl rutin.
【請求項3】 抗炎症剤が、グリチルリチン酸、グリチ
ルレチン酸、メフェナム酸、フェニルブタゾン、インド
メタシン、イブプロフェン、ケトプロフェン、アラント
イン、グアイアズレン及びそれらの誘導体並びにそれら
の塩、ε−アミノカプロン酸、酸化亜鉛、ジクロフェナ
クナトリウム、カンゾウ抽出物、アロエ抽出物、シコン
抽出物、サルビア抽出物、アルニカ抽出物、カミツレ抽
出物、シラカバ抽出物、オトギリソウ抽出物、ユーカリ
抽出物、ムクロジ抽出物から選ばれたものである請求項
1記載の皮膚外用剤。
3. The anti-inflammatory agent is glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, allantoin, guaiazulene and their derivatives, and salts thereof, ε-aminocaproic acid, zinc oxide, diclofenac. Claims which are selected from sodium, licorice extract, aloe extract, shikon extract, salvia extract, arnica extract, chamomile extract, birch extract, hypericum extract, eucalyptus extract, mukuroji extract The external preparation for skin according to 1.
JP6261943A 1994-09-30 1994-09-30 Skin external agent Pending JPH0899858A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6261943A JPH0899858A (en) 1994-09-30 1994-09-30 Skin external agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6261943A JPH0899858A (en) 1994-09-30 1994-09-30 Skin external agent

Publications (1)

Publication Number Publication Date
JPH0899858A true JPH0899858A (en) 1996-04-16

Family

ID=17368835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6261943A Pending JPH0899858A (en) 1994-09-30 1994-09-30 Skin external agent

Country Status (1)

Country Link
JP (1) JPH0899858A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09157151A (en) * 1995-12-05 1997-06-17 Noevir Co Ltd Melanin generation inhibitor and whitening agent
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US20100119469A1 (en) * 2008-11-12 2010-05-13 Draco Natural Products, Inc. Gynostemma extract surfactant/cleaning agent/emulsifier/foaming agent and method of producing same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09157151A (en) * 1995-12-05 1997-06-17 Noevir Co Ltd Melanin generation inhibitor and whitening agent
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US20100119469A1 (en) * 2008-11-12 2010-05-13 Draco Natural Products, Inc. Gynostemma extract surfactant/cleaning agent/emulsifier/foaming agent and method of producing same
US8557311B2 (en) * 2008-11-12 2013-10-15 DRACO Natural Products Gynostemma extract surfactant/cleaning agent/emulsifier/foaming agent and method of producing same

Similar Documents

Publication Publication Date Title
KR101364470B1 (en) Pharmaceutical composition for treating acne
JP2000095663A (en) Agent for external use containing plant extract
JP2929304B2 (en) Skin whitening preparation for external use
JPH07277939A (en) Skin external preparation
JP2540581B2 (en) Topical
JPH0665042A (en) Skin external preparation
JPH06336421A (en) External agent for skin
JPH11106311A (en) Hyaluronidase activity inhibitor and its use
JPH0533683B2 (en)
JPH0812560A (en) Skin external preparation
JPH0899860A (en) Skin external agent
JPH11349435A (en) Skin agent used for external use and effective for preventing and improving pigmentary symptom caused by ultraviolet light
JPH11139951A (en) Cosmetic
JPH09291012A (en) Antiphlogistic skin cosmetic
JPH0899858A (en) Skin external agent
JPH10330217A (en) Skin whitening preparation for external use
JPH11222412A (en) Skin preparation for external use
JPH05294819A (en) Beautifying cosmetic
JP2001322990A (en) Active oxygen scavenger and composition containing the same for erasing active oxygen
JPH10279464A (en) Skin preparation for external use
JP2003267882A (en) Skin cosmetic
KR20040056079A (en) Cosmetic composition for preventing and therapeutic for a pimple
JPH10279468A (en) Skin preparation for external use
JPH11302133A (en) Cosmetic for scalp and hair
JP3001121B2 (en) External preparation for skin